News from TCT: VOYAGER PAD and paclitaxel, STEMI in COVID-19 and more
Healio and Cardiology Today have curated a list of articles from the virtual TCT Connect.
Readers were most interested in the lack of a paclitaxel-related mortality signal in the VOYAGER PAD cohort, ticagrelor monotherapy after PCI for STEMI, outcomes of patients with STEMI and COVID-19 and more.
No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort
At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them. Read more
ILLUMENATE Global: DCB safe, effective in real-world cohort at 4 years
A low-dose paclitaxel-coated balloon was safe and effective at 4 years in real-world patients with peripheral artery disease, according to the ILLUMENATE Global results. Read more
Ticagrelor monotherapy reduces bleeding, does not impact ischemia after PCI for STEMI
Among patients with STEMI who underwent PCI with an ultrathin bioresorbable polymer sirolimus-eluting stent, switching to ticagrelor monotherapy after 3 months reduced bleeding risk, according to the TICO-STEMI trial. Read more
TMVR may improve survival in cardiogenic shock, mitral regurgitation
In cardiogenic shock, successful transcatheter mitral valve repair for moderate to severe mitral regurgitation showed signs of improving short- and intermediate-term survival. Read more
Patients with STEMI, COVID-19 represent ‘unique and high-risk’ population
Initial outcomes from the North American COVID-19 STEMI Registry provide a snapshot of the characteristics, presentation, treatment strategies and clinical outcomes of patients with STEMI and confirmed COVID-19. Read more
Novel mitral valve replacement system successfully treats mitral regurgitation
Mitral valve replacement using a novel transfemoral implantation system was successful in patients with severe mitral regurgitation at high surgical risk. Read more
Coronary intravascular lithotripsy beneficial in severely calcified lesions
Among patients with severely calcified coronary lesions, use of intravascular lithotripsy was associated with low rates of 30-day MACE and high rates of procedural success, according to the single-arm DISRUPT CAD III study. Read more
Transcatheter device may benefit patients with HF waiting for transplantation
A transcatheter device was a safe and effective bridge strategy to heart transplantation in patients with end-stage HF, with 23.5% removed from the list due to clinical improvement, researchers found in the MitraBridge registry. Read more
14-day DAPT with nanocoated stent inferior to standard short-term DAPT strategy
Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent. Read more
Bivalirudin may reduce risk for 30-day mortality after PCI in STEMI
Compared with heparin, bivalirudin reduced the risk for 30-day mortality, serious bleeding and net adverse clinical events in patients with STEMI undergoing PCI despite increased rates of stent thrombosis and MI, researchers found. Read more